Next Phase Newsletter

A pharmaceutical company dedicated to research, development, and commercialization of innovative products for unmet medical needs in the areas of musculoskeletal disorders, including pain management and critical care, is vastly investing to expand their presence from its domestic roots to become a Global Specialty Pharma. To achieve above goal, the firm is looking for opportunities of early stage pipelines and/or research collaborations with global rights to expand their business worldwide.

The firm Is pursuing attractive, new in-licensing and research collaboration opportunities in the following areas of interest: in relation to in-licensing opportunities in pre-clinical stage for the global market, the firm is interested in chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, and muscle-related disorders (i.e. DMD, ALS, etc.) In relation to research collaboration opportunities for the global market, the firm is interested in drug seeds for chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, as well as platform technologies related to drug delivery, formulation, excipients, oral, transdermal, nanoparticle, controlled release, and targeting.

The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm will seek global rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A therapeutic accelerator looks to in-license therapeutics assets from inventors/founders, and fund the assets’ development through clinical proof-of-concept. The firm is looking for assets throughout the United States and is actively seeking new opportunities. The firm has signed a partnership with a major VC firm, who will advise on current and future investments.

The firm is currently looking for therapeutic assets in pre-clinical through early clinical stages of development. The firm is open in terms of indication and will consider both small molecules and biologics, and will also consider drug repurposing opportunities. The firm looks to in-license these assets and accelerate their development through to clinical proof-of-concept, at which point the firm looks to partner the asset with pharmaceutical firms or other investors who will complete the commercialization of the asset. The firm has signed strategic partnerships with major pharma, regarding products in cardiovascular, metabolic, neuroscience, and immunology indications.

The firm focuses on the strength of the technology when evaluating in-licensing opportunities. The company leverages a capable and connected team and advisors for the development, funding, active management, and partnering of its portfolio of therapeutic products.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture firm headquartered in USA invests $1-10M in Seed stage and beyond, with Series A being their sweet spot. Because of the flexibility in their balance sheet and investment committee, the firm has also looked at investments greater than $10M in Series C and D companies. The firm typically makes equity investments but has used notes for later stage investments. The firm is USA focused; however, the firm will look at companies headquartered elsewhere if there’s USA commercial traction or intent to commercialize in the US.

The firm is interested in diagnostic and digital health sectors and is open to all subsectors and indications. The firm is not interested in therapeutics or medical devices, unless they’re noninvasive medical devices. The firm is especially interested in technology that impacts their polychronic patients, especially since the firm has a strong intention of moving upstream into the CKD and ESKD space. The firm has done a lot of work in the cardiometabolic and comorbidity space, more specifically looking at technology for cardiovascular disease, diabetes, COPD, social determinants of health, end of life and behavioral health.

The firm is open to all types of management teams but have a preference for entrepreneurial experience, however the firm has also backed first time founders. For companies not in the diagnostics or device space, the firm likes to see at least $1M in ARR. They firm has led in the past but prefers to join syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with USA and Europe offices is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities, but focuses on USA and Europe-based companies.

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic, but tend to stray away from cardiovascular and CNS indications.

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and China manages both RMB and USD funds. The firm’s USD fund has invested in 7 companies, half of which are in the novel drugs area, and will continue to invest in seed to pre-Series A. The typical allocation size is $0.5-1 MM, and will occasionally go up to $3.5 MM.

The firm is mainly interested in therapeutics innovations, including orphan drugs, from pre-clinical to Phase II. Of special interest are: CAR-T, small molecules and CRISPR technologies. The firm is also open to medical device companies, from development to clinical stage, but holds a strict valuation on diagnostics companies. The firm is less interested in digital health.

The firm has no specific company & management team requirements. Diversity in gender and race is greatly encouraged.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital / growth equity firm located in New York City. The firm focuses on the Life Science Industrials and invests in companies that develop tools, technologies, and services for discovery, development, and manufacturing of biologics and related therapies. The firm is focused on early stage venture and growth equity investments. Typical equity investments range from $500k-$7 million. The firm has $65M AUM, 10 active portfolio companies to date, and is open to leading or co-leading in a financing round.

Within life sciences, the firm is specifically focused on life science industrials: the tools, technologies, and services that enable the discovery, development, and manufacturing of life-saving therapies. The firm does not invest in therapeutics or medical devices. The firm considers Seed to Series B stage opportunities.

The firm partners with entrepreneurs and their teams to overcome inflection points in growth. The firm takes a hands-on approach to working with its portfolio companies through focused operational and commercial guidance and an engaged approach to supporting entrepreneurial ventures.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Based in Toronto, Canada, A healthcare venture capital firm typically makes equity investments into digital health and AI-enabled medical device companies at seed/series A-B stages and follow on rounds. The typical investment size ranges from $1.5 million to $ 7 million. The firm seeks to invest in approx. 2-5 digital health/AI-enabled medical device companies per year and focuses on companies based in North America, Europe and the GCC region.

The firm is currently looking for new investment opportunities in the Digital Health and AI-enabled Medical Device spaces. The firm is opportunistic in terms of indications. The firm prefers to invest in non-invasive device companies with clinical validation and some in-human data with a clear path to clinical adoption & reimbursement. For Digital Health, the firm prefers to invest in companies developing data platforms aimed at improving outcomes or processes, with first market pilots complete and approximately $250k ARR.

The firm seeks to invest in private companies. The firm considers pre-revenue companies, depending on sector and in companies who have has a strong commercial and technical management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.